What happens to intolerant, relapsed or refractory chronic myeloid leukemia patients without access to clinical trials?

What happens to intolerant, relapsed or refractory chronic myeloid leukemia patients without access to clinical trials?

Objective: To assess clinical outcomes of intolerant, relapsed or refractory patients who could not be treated with new tyrosine kinase inhibitors or experimental therapies. Methods: A retrospective cohort of 90 chronic myeloid leukemia patients in all phases of the disease treated with imatinib mes...

Full description

Bibliographic Details
Main Authors: Guilherme Rasia Bosi, Laura Maria Fogliatto, Tito Emilio Vanelli Costa, Kamila Castro Grokoski, Mariana Pinto Pereira, Nathan Bugs, Marco Kalil, Christina Fraga, Liane Esteves Daudt, Lucia Mariano da Rocha Silla
Format: Article
Language:English
Published: Elsevier 2019-07-01
Series:Hematology, Transfusion and Cell Therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2531137919300288

Internet

http://www.sciencedirect.com/science/article/pii/S2531137919300288

Similar Items